Allogene Therapeutics has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of ALLO-316, an AlloCAR T investigational product for the treatment of advanced or metastatic renal cell carcinoma (RCC). ALLO-316 targets CD70, which is highly expressed in RCC and is also selectively expressed in several cancers. […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!